Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
27/03/2025 12:51
March 27 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A: ACTINIUM PHARMACEUTICALS ANNOUNCES ATNM-400 A NOVEL NON-PSMA TARGETING FIRST IN CLASS PROSTATE CANCER RADIOTHERAPY LEVERAGING ACTINIUM-225 ACTINIUM PHARMACEUTICALS INC -99.8% TUMOR GROWTH INHIBITION ACHIEVED WITH A SINGLE DOSE OF ATNM-400 IN PRECLINICAL PROSTATE CANCER MODELS Source text: ID:nPn7tG4gVa Further company coverage: ATNM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities